We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy These 3 Health Care Mutual Funds for a Volatile Market
Read MoreHide Full Article
Minutes from the Federal Reserve's Federal Open Market Committee (FOMC) meeting held March 17-18 highlighted the need to combat higher inflation while supporting an improving economy. At the FOMC meeting of 2026 held Jan. 26-27, the benchmark interest rate was set at 3.50-3.75%. While some FOMC members said they would consider raising interest rates to combat higher inflation if it continues, others said an economic slowdown caused by geopolitical conflict could at some point justify a cut in interest rates.
Over the past month, the war between the United States and Iran has created uncertainty in the economic outlook, with a sharp rise in oil prices. Although oil prices later eased following a temporary ceasefire, this created uncertainty in the markets.
With much uncertainty and a volatile nature in the overall market, health care mutual funds have become attractive options for investment. The medical services, pharmaceuticals and medical devices sector is non-volatile in nature and is largely independent of interest rate fluctuations as well as energy-driven inflation. In general, the beta for health care companies is relatively low, which implies lower volatility in their stock prices when compared to the overall market. These are essential services that provide vital healthcare solutions to mankind and are therefore certain to attract customers in bad times as well as good times.
We have chosen three healthcare mutual funds, Franklin Biotechnology Discovery Fund ((FBDIX - Free Report) ), Fidelity Select Pharmaceuticals Port ((FPHAX - Free Report) ), and Janus Henderson Global Life Sciences ((JNGLX - Free Report) ), which investors should buy now for the long term. These funds have a Zacks Mutual Fund Rank #1 (Strong Buy) or 2 (Buy), positive three-year and five-year annualized returns, minimum initial investments within $5000 and expense ratios considerably lower than the category average. So, these funds have provided a comparatively stronger performance and carry a lower fee.
Franklin Biotechnology Discovery Fund seeks capital appreciation. FBDIX invests most of its net assets in equity securities of biotechnology companies and discovery research firms worldwide, including therapeutics, drug delivery, gene therapy, and other select medical companies.
Evan S. McCulloch has been the lead manager of FBDIX since Sept. 15, 1997. Most of the fund’s holdings were in companies like Gilead Sciences, Inc. (5.6%), Vertex Pharmaceuticals Inc (4.6%) and Amgen Inc. (4.5%) as of Oct. 31, 2025.
FBDIX’s 3-year and 5-year annualized returns are 24.6% and 6.6%, respectively. Its net expense ratio is 1.05%. FBDIX has a Zacks Mutual Fund Rank #1.
To see how this fund performed compared to its category, and other 1 and 2 Ranked Mutual Funds, please click here.
Fidelity Select Pharmaceuticals Port fund seeks capital appreciation. FPHAX invests a majority of its assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all kinds.
Karim Suwwan de Felipe has been the lead manager of FPHAX since July 1, 2007. Most of the fund’s holdings were in companies like Eli Lilly and Co (24.7%), AstraZeneca PLC (11.2%), and Johnson & Johnson (5.4%) as of Nov. 30, 2025.
FPHAX’s 3-year and 5-year annualized returns are 21.8% and 13.4%, respectively. Its net expense ratio is 0.68%. FPHAX has a Zacks Mutual Fund Rank #1.
Janus Henderson Global Life Sciences fundprimarily invests in companies with a life sciences focus, allocatinga significant portion to that sector, guided by portfolio management’s assessment and maintaining a dedicated exposure to life sciences industries.
Andy Acker has been the lead manager of JNGLX since May 1, 2007. Most of the fund’s holdings were in companies like Eli Lilly and Co (9.7%), Johnson & Johnson (5.6%) and AstraZeneca PLC (4.3%) as of Dec. 31, 2025.
JNGLX’s 3-year and 5-year annualized returns are 14.1% and 8.4%, respectively. Its net expense ratio is 0.81%. JNGLX has a Zacks Mutual Fund Rank #1.
Want key mutual fund info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week.Get it free >>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Buy These 3 Health Care Mutual Funds for a Volatile Market
Minutes from the Federal Reserve's Federal Open Market Committee (FOMC) meeting held March 17-18 highlighted the need to combat higher inflation while supporting an improving economy. At the FOMC meeting of 2026 held Jan. 26-27, the benchmark interest rate was set at 3.50-3.75%. While some FOMC members said they would consider raising interest rates to combat higher inflation if it continues, others said an economic slowdown caused by geopolitical conflict could at some point justify a cut in interest rates.
Over the past month, the war between the United States and Iran has created uncertainty in the economic outlook, with a sharp rise in oil prices. Although oil prices later eased following a temporary ceasefire, this created uncertainty in the markets.
With much uncertainty and a volatile nature in the overall market, health care mutual funds have become attractive options for investment. The medical services, pharmaceuticals and medical devices sector is non-volatile in nature and is largely independent of interest rate fluctuations as well as energy-driven inflation. In general, the beta for health care companies is relatively low, which implies lower volatility in their stock prices when compared to the overall market. These are essential services that provide vital healthcare solutions to mankind and are therefore certain to attract customers in bad times as well as good times.
We have chosen three healthcare mutual funds, Franklin Biotechnology Discovery Fund ((FBDIX - Free Report) ), Fidelity Select Pharmaceuticals Port ((FPHAX - Free Report) ), and Janus Henderson Global Life Sciences ((JNGLX - Free Report) ), which investors should buy now for the long term. These funds have a Zacks Mutual Fund Rank #1 (Strong Buy) or 2 (Buy), positive three-year and five-year annualized returns, minimum initial investments within $5000 and expense ratios considerably lower than the category average. So, these funds have provided a comparatively stronger performance and carry a lower fee.
Franklin Biotechnology Discovery Fund seeks capital appreciation. FBDIX invests most of its net assets in equity securities of biotechnology companies and discovery research firms worldwide, including therapeutics, drug delivery, gene therapy, and other select medical companies.
Evan S. McCulloch has been the lead manager of FBDIX since Sept. 15, 1997. Most of the fund’s holdings were in companies like Gilead Sciences, Inc. (5.6%), Vertex Pharmaceuticals Inc (4.6%) and Amgen Inc. (4.5%) as of Oct. 31, 2025.
FBDIX’s 3-year and 5-year annualized returns are 24.6% and 6.6%, respectively. Its net expense ratio is 1.05%. FBDIX has a Zacks Mutual Fund Rank #1.
To see how this fund performed compared to its category, and other 1 and 2 Ranked Mutual Funds, please click here.
Fidelity Select Pharmaceuticals Port fund seeks capital appreciation. FPHAX invests a majority of its assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all kinds.
Karim Suwwan de Felipe has been the lead manager of FPHAX since July 1, 2007. Most of the fund’s holdings were in companies like Eli Lilly and Co (24.7%), AstraZeneca PLC (11.2%), and Johnson & Johnson (5.4%) as of Nov. 30, 2025.
FPHAX’s 3-year and 5-year annualized returns are 21.8% and 13.4%, respectively. Its net expense ratio is 0.68%. FPHAX has a Zacks Mutual Fund Rank #1.
Janus Henderson Global Life Sciences fund primarily invests in companies with a life sciences focus, allocating a significant portion to that sector, guided by portfolio management’s assessment and maintaining a dedicated exposure to life sciences industries.
Andy Acker has been the lead manager of JNGLX since May 1, 2007. Most of the fund’s holdings were in companies like Eli Lilly and Co (9.7%), Johnson & Johnson (5.6%) and AstraZeneca PLC (4.3%) as of Dec. 31, 2025.
JNGLX’s 3-year and 5-year annualized returns are 14.1% and 8.4%, respectively. Its net expense ratio is 0.81%. JNGLX has a Zacks Mutual Fund Rank #1.
Want key mutual fund info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week.Get it free >>